$OBIO Balance Sheet | Understand Stock

$OBIO

$5.78 +$0.23 (4.14%) Close

$OBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
Prepaid expenses
Marketable securities
Strategic investments, current portion
Accounts receivable, net
Inventory
Prepaid expenses and other current assets
Total current assets
Cash and investments held in Trust Account

Property and equipment, net
Right-of-use assets
Strategic investments, less current portion
Strategic investments
Deposits and other assets
TOTAL ASSETS
LIABILITIES, SERIES A PREFERRED STOCK AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable
Accrued expenses and other liabilities
Accrued expenses - related party
Operating lease liability, current portion
Warrant liability
Deferred revenue, current portion
Loan payable, current portion
Total current liabilities
Deferred underwriting commissions

Deferred revenue, less current portion
Royalty purchase agreement
Note payable
Loans payable
Derivative liability
Operating lease liability, less current portion
Other long-term liabilities
TOTAL LIABILITIES
Ordinary shares subject to possible redemption, $0.0001 par value; 6,762,117 and 16,000,000 shares issued and outstanding at approximately $10.01 and $10.00 per share redemption value as of December 31, 2022 and 2021, respectively
Series A Preferred Stock, $0.0001 par value per share; 200,000 issued and outstanding at June 30, 2026 and December 31, 2025; aggregate liquidation preference of $20,000
STOCKHOLDERS' EQUITY
Common stock, $0.0001 par value per share; 340,000,000 shares authorized; 60,105,049 and 57,032,963 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.
Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Total shareholders’ deficit
TOTAL STOCKHOLDERS' EQUITY
TOTAL LIABILITIES, SERIES A PREFERRED STOCK AND STOCKHOLDERS' EQUITY

Comments